List of Relistor drug patents

Relistor is owned by Salix Pharms.

Relistor contains Methylnaltrexone Bromide.

Relistor has a total of 8 drug patents out of which 0 drug patents have expired.

Relistor was authorised for market use on 24 April, 2008.

Relistor is available in solution;subcutaneous dosage forms.

Relistor can be used as treatment of opioid-induced constipation.

The generics of Relistor are possible to be released after 31 December, 2030.

RELISTOR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025 SALIX PHARMS Stable methylnaltrexone preparation
Apr, 2024

(1 year, 12 days from now)

US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 12 days from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(1 year, 12 days from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Dec, 2030

(7 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 24 April, 2008

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

RELISTOR family patents

21

United States

8

Japan

7

European Union

5

China

4

Australia

4

Portugal

4

Spain

4

Poland

4

New Zealand

3

Israel

3

Denmark

3

Hong Kong

3

Slovenia

3

Russia

3

Brazil

3

Croatia

3

Cyprus

3

Canada

2

Mexico

2

Korea, Republic of

1

Singapore

1

Argentina

Relistor is owned by Salix.

Relistor contains Methylnaltrexone Bromide.

Relistor has a total of 9 drug patents out of which 0 drug patents have expired.

Relistor was authorised for market use on 19 July, 2016.

Relistor is available in tablet;oral dosage forms.

Relistor can be used as treatment of opioid-induced constipation.

The generics of Relistor are possible to be released after 10 March, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(6 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone
Mar, 2031

(7 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 19 July, 2016

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of RELISTOR before it's patent expiration?
More Information on Dosage

RELISTOR family patents

21

United States

9

Japan

7

New Zealand

6

European Union

5

China

4

Singapore

4

Korea, Republic of

3

Israel

3

Mexico

3

Brazil

3

Poland

2

Australia

2

Hong Kong

2

Russia

2

Argentina

2

Spain

2

Taiwan, Province of China

2

Ukraine

2

Canada

1

South Africa

1

Morocco

1

Hungary

1

Costa Rica

1

Colombia

1

Portugal

1

Guatemala

1

Malaysia

1

Peru

1

Chile

1

Ecuador

1

Georgia

EA

1

EA

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in